Mechanisms and management of prothrombotic state in COVID-19 disease.
- Published in:
- Therapeutic Advances in Cardiovascular Disease, 2021, p. 1, doi. 10.1177/17539447211053470
- By:
- Publication type:
- Article
Works matching IS 17539447 AND DT 2021
Results: 7
1
2
Modulating inflammation to reduce atherosclerotic cardiovascular events: should colchicine be part of the therapeutic regimen?
- Published in:
- Therapeutic Advances in Cardiovascular Disease, 2021, p. 1, doi. 10.1177/17539447211042714
- By:
- Publication type:
- Article
3
Impact of body mass index on 90-day warfarin requirements: a retrospective chart review.
- Published in:
- Therapeutic Advances in Cardiovascular Disease, 2021, p. 1, doi. 10.1177/17539447211012803
- By:
- Publication type:
- Article
4
Epidemiology of infective endocarditis before versus after change of international guidelines: a systematic review.
- Published in:
- Therapeutic Advances in Cardiovascular Disease, 2021, p. 1, doi. 10.1177/17539447211002687
- By:
- Publication type:
- Article
5
The dawn of the four-drug era? SGLT2 inhibition in heart failure with reduced ejection fraction.
- Published in:
- Therapeutic Advances in Cardiovascular Disease, 2021, p. 1, doi. 10.1177/17539447211002678
- By:
- Publication type:
- Article
6
Trace elements in patients with aortic valve sclerosis.
- Published in:
- Therapeutic Advances in Cardiovascular Disease, 2021, p. 1, doi. 10.1177/1753944720985985
- By:
- Publication type:
- Article
7
Vasopressin antagonism in heart failure: a review of the hemodynamic studies and major clinical trials.
- Published in:
- Therapeutic Advances in Cardiovascular Disease, 2021, v. 15, p. 1, doi. 10.1177/1753944720977741
- By:
- Publication type:
- Article